Follow us on Twitter
twitter icon@FreshPatents

G Protein patents

      

This page is updated frequently with new G Protein-related patent applications.




 Release reagent for vitamin d compounds patent thumbnailnew patent Release reagent for vitamin d compounds
A reagent composition for releasing vitamin d compounds bound to vitamin d-binding protein and an in vitro method for the detection of a vitamin d compound in which the vitamin d compound is released from vitamin d-binding protein by the use of this reagent composition as well as the reagent mixture obtained in this manner. Also disclosed is the use of the reagent compositions to release vitamin d compounds as well as a kit for detecting a vitamin d compound..
Roche Diagnostics Operations, Inc.


 Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and  using same patent thumbnailnew patent Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and using same
Where x is an n-hydroxy-succinimidyl or similar heterocyclic group. Also provided is a method of mapping protein-protein interactions of protein complexes using various mass spectrometry techniques..

 Methods and kits for diagnosing, prognosing and monitoring parkinson's disease patent thumbnailnew patent Methods and kits for diagnosing, prognosing and monitoring parkinson's disease
Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (hnf4a), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of pd patients. In parallel, the polypyrimidine tract binding protein 1 (ptbp1), involved in the stabilization and mrna translation of insulin, was identified as the most downregulated gene.
Rosalind Franklin University Of Medicine And Science


 Protein demethylases comprising a jmjc domain patent thumbnailnew patent Protein demethylases comprising a jmjc domain
Post-translational modification, including protein methylation, plays an important role in regulating protein function. The present invention provides a novel assay for evaluating demethylase activity and the discovery of a family of protein demethylases comprising a novel demethylase motif..
The University Of North Carolina At Chapel Hill


 Methods for making proteins containing free cysteine residues patent thumbnailnew patent Methods for making proteins containing free cysteine residues
The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness.
Bolder Biotechnology, Inc.


 Protein scaffolds and methods of use patent thumbnailnew patent Protein scaffolds and methods of use
This disclosure describes non-naturally occurring protein scaffolds and methods of making and using the protein scaffolds. In one aspect, therefore, this disclosure describes a non-naturally occurring protein scaffold that includes a plurality of structural domains and a plurality of loop regions that include an amino acid sequence that varies from a naturally-occurring loop region by at least one amino acid deletion, substitution, or addition.
Regents Of The University Of Minnesota


 Method of extracting protein patent thumbnailnew patent Method of extracting protein
The present disclosure provides a method for extracting a soluble protein from a population of microorganisms, the method comprising contacting the population of microorganisms expressing the soluble protein with an amount of a solution comprising from about 1% (v/v) to less than 50% (v/v) carboxylic acid effective to extract the soluble protein from the population of microorganisms.. .
Elastagen Pty Ltd


 Inhibitors of metallo-beta-lactamase (mbl) comprising a zinc chelating moiety patent thumbnailnew patent Inhibitors of metallo-beta-lactamase (mbl) comprising a zinc chelating moiety
Compounds according to formula i are provided: a-l-b wherein a represents a lipophilic chelating moiety which is selective for zn2+ions; l is a covalent bond or a linker; and b is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-β-lactamase or dd-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. A method of treating and/or preventing a bacterial infection in a human or non-human mammal employing such compounds are also provided.
Universitetet I Oslo


 Vaccine comprising protein nmb0964 from neisseria meningitidis patent thumbnailnew patent Vaccine comprising protein nmb0964 from neisseria meningitidis
The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the nmb0964 antigens such that bactericidal antibodies are generated against said antigen. It has been found for the first time that this antigen's expression is zinc regulated and therefore methods are provided to upregulated expression through removal of the zinc repression mechanism of the cell or promoter, or through removal of zinc from the culture medium..
Glaxosmithkline Biologicals S.a.


 Kinase modulation, and indications therefor patent thumbnailnew patent Kinase modulation, and indications therefor
The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from fms protein kinase including any mutations thereof, kit protein kinase any mutations thereof, flt-3 protein kinase any mutations thereof and combinations thereof.. .
Plexxikon Inc.


new patent

Article and controlling oral-originated obligate and facultative anaerobes and aerobic bacteria pathogens related to systemic disease


Method of treating oral subgingival biofilms having obligate anaerobes, facultative anaerobes, aerobic bacteria and other micro-organisms (collectively oral pathogens) associated with certain systemic diseases present within a subgingival biofilm having proteins and amino acids, the steps including providing a periodontal medicament delivery tray having a seal against a patient's adjacent gums containing the oral biofilms with the systemic disease, said seal formed so as to have no contact with teeth, applying to the gingival tissue (sulcus or periodontal pocket) a biofilm penetrating antimicrobial agent, removing the imbedded oral pathogens from the gingival tissue following at least one applying of the antimicrobial agent to the gingival tissue; repeatedly administering colloidal hydrogen peroxide gel to the gingival tissue following the removing; and following each administering cleaning the gingival tissue with a cleaning agent directly following the administering of the colloidal hydrogen peroxide gel for modifying the environment from anaerobic to commensal.. .

Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip


Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University


Method for detecting proteins by means of aptamers


The present invention describes a method for an in vitro detection of a first protein in a sample, comprising the steps of: a) separating the sample by means of a native separation method; b) transferring the separated sample onto a membrane; c) contacting the membrane with an aptamer which specifically binds to the first protein; and d) detecting the first protein by detecting the aptamer bound to the first protein.. .
Technische Universität Berlin


Method for selecting a single cell expressing a heterogeneous combination of antibodies


Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


Pumilio domain-based modular protein architecture for rna binding


A programmable modular protein architecture for rna binding comprises a set of modules, derived from rna-binding protein pumilio, that can be concatenated into chains of varying composition and length. When bound into a chain, each module has a preferred affinity for a specific rna base.
Massachusetts Institute Of Technology


Genetic testing for improved cattle fertility


Arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods based on novel snps on genes of the bovine transforming growth factor-β (tgf-β) signaling pathway for improved bovine fertilization rate. The methods and compositions of the present invention are related to snps in the dna-binding protein inhibitor 3 (id3) gene, and in the bone morphogenetic protein 4 (bmp4) gene corresponding to position 2702 of seq id no: 2.
Wisconsin Alumni Research Foundation


Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)


The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing sturge-weber syndrome (sws), klippel-trenaunay-weber syndrome (ktws), and port wine stains (pws).
Duke University


Microbial analysis


The present invention is concerned with a method of identifying microbial strains (e.g. From a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % meoh; ii) a sample preparation step, comprising preparation of a maldi sample incorporating the extracted lipids; iii) a data gathering step, comprising performing maldi-based mass spectrometry on the maldi sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain.
Kratos Analytical Limited


Methods for the selection of binding proteins


This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
Bristol-myers Squibb Company


Synthetic single domain antibody


The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d ab) and its use in generating synthetic single domain antibody library (hs2d ab-l1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics..
Centre National De La Recherche Scientifique - Cnrs


Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies


Method for improving blood persistence of protein


Provided herein is a means for increasing protein retention in blood. The protein retention in blood is increased by forming a conjugate of a protein and chondroitin produced by a microorganism having chondroitin-producing capability and/or chondroitin synthesized with a chondroitin synthase..
Seikagaku Corporation


Chimeric factor h binding proteins (fhbp) and methods of use


Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


Compositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery


The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. .
University Medical Center Utrecht, The Netherlands


Immuno-oncolytic therapies


The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces t cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce tlr2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic t lymphocyte induction (e.g., trif) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin e2 reduces tumor growth.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases


This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (dr) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser ophthalmoscope.
Massachusetts Eye And Ear Infirmary


Activated formylglycine-generating enzymes and methods of producing and using the same


The present disclosure provides activated formylglycine-generating enzymes (fge), methods of producing activated fge, and their use in methods of producing a protein comprising a formylglycine (fgly) residue. The methods of producing activated fge, as well as methods of use of activated fge in producing fgly-containing proteins, include both cell-based and cell-free methods.
R.p. Scherer Technologies, Llc


Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Tm4sf1 binding proteins and methods of using same


This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


Photoreactive synthetic regulator of protein function and methods of use thereof


The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator.
The Regents Of The University Of California


Inhibitors of valosin-containing protein and methods of use


A method of inhibiting aberrant valosin-containing protein (vcp) accumulation in the mitochondria of a nerve cell includes administering to the nerve cell a therapeutic agent that inhibits the binding or complexing of vcp with a polyglutamine protein.. .
Case Western Reserve University


Stable solid units and methods of making the same


The invention provides stable solid compositions of a therapeutic agent, such as a protein, (e.g., an antibody, a peptide, or a dvd-ig protein), and a stabilizer, such as a sugar, and methods of preparing and using the same. The invention further provides a generalized therapeutic agent delivery form wherein the active components are in a lyophilized, stable configuration, and, in some embodiments, prepared independently from the primary container..
Abbvie Inc.


Methods and kits for isolation and analysis of a chromatin region


The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas


Modified zinc finger binding proteins


Disclosed herein are compositions and method comprising non-canonical (e.g., non-c2h2) zinc finger proteins.. .
Sangamo Biosciences, Inc.


Material and methods for treating or preventing her-3 associated diseases


Described herein are materials and methods for treating subjects having a her-3 associated disease, by administering a first agent that binds to her-3, in combination with a second agent that binds and/or inhibits another member of the her family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example..
Amgen, Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fusion protein


The present invention relates to a p75ntr neurotrophin binding protein(nbp)-fc fusion protein comprising a p75n-tr(nbp) portion and an immunoglobulin portion. In certain embodiments, the p75ntr(nbp)-fc fusion protein is for use in the treatment of pain and/or a symptom of pain..
Levicept Ltd


Fc-binding protein, producing said protein, and antibody adsorbent using said protein, and methods for purifying and identifying antibody using said adsorbent


The present invention addresses the first problem of providing an fc-binding protein having improved stability, especially stability to heat and acid, of the fc-binding protein, a method for producing this protein, and an antibody adsorbent using this protein. The present invention also addresses the second problem of providing a method that makes it possible to identify the presence or absence of glycosylation of an antibody, and a material to be used in this method.
Tosoh Corporation


Method for producing protein by precipitation


(4) dissolving the solid separated in step (3) into a solution having a ph of 12 or below but higher than the ph of the solution obtained in step (2) by 0.1 or more.. .

Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases


On the basis thereof, the authors of the present invention have combined a peptide, a protein or a polypeptide associated with a “conformational disease” with a biologically active or functional hsp, resulting in a different immunoactive complex which is advantageous for treating the “conformational disease” in question associated with the peptide, protein or polypeptide used.. .

Extracts of curcuma amada and uses thereof


The invention concerns carbon dioxide extracts of curcuma amada (mango ginger), including supercritical carbon dioxide extracts of c. Amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of bcl-2, bak, and p53 genes; inhibiting expression of the cox-2 and nf-kb genes, inhibiting production of phosphorylated target of rapamycin (tor), modulating amp-activated protein kinase (ampk), inhibiting protein kinase b (akt) signaling, modulating the ras/raf/mek/erk signaling pathway, and modulating the ras/pi3k/pten/akt/mtor signaling pathway.
Flavex Naturextrakte Gmbh


Pharmaceutical or nutraceutical composition


The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions.

Vitamin d complexes with de-vdbp and an unsaturated fatty acid, and their use in therapy


A family of potent, stable vitamin d-based complexes for therapeutic use in chronic diseases such as cancer, neuro-degenerative diseases, chronic kidney disease and hiv infection is disclosed. They may be made by interaction with de-glycosylated vitamin d-binding protein to form a dimeric complex which can be further stabilized by unsaturated fatty acids to form a trimeric complex which provides improved interaction at cellular level with the vitamin d receptor at the plasma membrane.

Common light chain mouse


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


G protein coupled receptors and uses thereof


The present invention provides gpcr polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders.
Omeros Corporation


Identifying molecular systems in protein sequence data


Methods for identifying a molecular system that is similar to at least one model molecular system are provided. The methods may comprise a) establishing an inventory including genetic content, genomic organization and at least one discriminating trait for at least one model molecular system; b) determining from the inventory(ies) of step a) a non-redundant list of protein components of the at least one model molecular system; c) associating a protein component profile encoded by a hidden markov model (hmm) for each non-redundant protein component; d) providing at least one set of protein sequences obtained from genome data corresponding to a contig of an ordered sequence dataset; e) similarity searching the set of protein sequences obtain from genome data with the protein component profiles of c); f) selecting hit proteins that match the searched protein component profiles from among the set of protein sequences obtain from genome data; g) building clusters using hit proteins selected in step f) according to the genomic organization specified for the model molecular system; h) selecting clusters including protein components of a single model molecular system according to the genetic content and discriminating traits specified for the model molecular system; and i) filling inventories of compatible model molecular systems using clusters from step h)..
Centre National De La Recherche Scientifique (cnrs)


Icos binding proteins


The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited


Il-18 binding protein (il-18bp) in inflammatory diseases


The present invention provides means and methods for treating interleukin 18 (il-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free il-18 and il-18 binding protein (il-18bp) for use in such treatments and for the diagnosis of the indications..
Ab2 Bio Sa


Interleukin-4 receptor-binding fusion proteins and uses thereof


The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic bcl-2 family member protein moiety..
Medicenna Biopharma Inc.


Biomarkers for mycobacterium avium paratuberculosis (map)


Described are methods and products useful for identifying subjects with mycobacterium avium subspecies paratuberculosis (map). A number of protein antigens secreted into culture filtrate by map are identified and binding proteins selective for these antigens are demonstrated to be useful for detecting subjects with map infections including subjects with johne's disease..
University Of Guelph


Multimeric immunoglobulin-binding domain


A multimeric immunoglobulin-binding protein having improved properties as an affinity ligand for affinity chromatography, and an insoluble support inmmobilizing such a multimer. The immunoglobulin-binding protein is represented by the formula: (r1)n-(r2)m, or (r2)m-(r1)n.
Protenova Co., Ltd.


Memory performance and prevention and treatment of neurodegenerative diseases


The present technology relates to improvement of memory performance and the prevention or treatment of brain disorders associated with memory loss. In particular, the invention relates to the use of centaurin-α1 (centa1), centa1 activating proteins, and centa1 effector proteins as therapeutic targets to improve memory and cognitive performance in a normal subject and/or in a subject with neurological disorders associated with memory and/or cognitive impairments, such as alzheimer's disease..
Max Planck Florida Institute For Neuroscience


System and increasing learning through eating protein, exercising, and singing and preventing bullying


A system and method of enhancing learning through a combination exercising, singing, and eating protein is provided. The method includes the steps of exercising in place for five minutes, singing a song, sitting in silence, eating the protein-based food, and commencing a teaching or training session.

Methods and predicting protein structure


The present invention relates to a method for predicting three-dimensional structure of a protein from its sequence. Three-dimensional structure may be determined by: (a) generating a multiple sequence alignment for a candidate protein having a known sequence; (b) identifying a covariance matrix between all pairs of sequence positions in the multiple sequence alignment; (c) inverting the covariance matrix and identifying predicted evolutionary constraints using a statistical model of the candidate protein; and (d) simulating folding of an extended chain structure of the candidate protein using the predicted constraints..
President And Fellows Of Harvard College


Foam-jetting member for protein crystal device and protein crystal-adsorbing foam-jetting member, protein crystal device and crystallizing protein, and protein crystal cutting device and cutting protein crystal


Provided are a protein crystal device and method for crystallizing protein capable of generating protein crystal without imparting a heat effect, a protein crystal-cutting device and method for cutting protein crystal capable of cutting protein crystal without imparting a heat effect on protein crystal, and bubble-jetting member and protein-adsorbing-bubble-jetting member used in said device. A bubble-jetting member is used in a protein crystal device to jet bubbles into a protein solution to thereby allow protein crystals to be obtained, the bubble-jetting member comprising: a core formed of a conductive material; a shell part formed of an insulating material, including an extended section extending from the tip of the core, and in which at least a portion closely adheres to the core to cover the core; and a gap having a bubble-jetting port, the gap being formed between the extended section and the tip of the core..
Japan Science And Technology Agency


Blood clot-dissolving proteins produced in seeds


Transgenic plants in which blood-clot dissolving proteins are produced in seeds of the plants are provided. Expression of the proteins is driven by a seed specific or selective promoter.
Northeastern State University


Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization


Spin labeled ice binding compounds (ibcs) including ice binding proteins (ibps), also called antifreeze proteins (afps) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (dnp), for enhancing nuclear magnetic resonance (nmr) signal intensities. Use of spin labeled ibcs to perform dnp exploits the ibcs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high dnp efficiency.
The Trustees Of California State University


Peptides inhibiting cold-inducible rna binding protein activity


Disclosed are pharmaceutical compositions comprising a cirp inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a cirp inhibitor are also described herein..
The Feinstein Institute For Medical Research


Heteroaryl amides as inhibitors of protein aggregation


The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as parkinson's disease, alzheimer's disease, lewy body disease, parkinson's disease with dementia, fronto-temporal dementia, huntington's disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.. .
Neuropore Therapies, Inc.


Materials and methods for modulating disc1 turnover


The invention relates to the finding that turnover of disc1 (disrupted in schizophrenia 1) is mediated by the f-box-containing protein fbxw7 (f-box/wd repeat-containing protein 7). The sequence within disc1 that binds to fbxw7 and targets disc1 for turnover by the ubiquitin-proteasome system is identified.
The University Court Of The University Of Glasgow


Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling


The present invention provides use of an inhibitor of g protein-coupled receptor cxcr4 for treating amyotrophic lateral sclerosis (als), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.. .
Ramot At Tel-aviv University Ltd.


Solution for dissociating vitamin d from vitamin d-biding protein, associated detection method and use


At least one fluoroalkyl surfactant and of at least one alcohol having 1 to 4 carbon atoms are used for dissociating vitamin d and/or a vitamin d metabolite from vitamin d binding protein. A solution comprising the at least one fluoroalkyl surfactant and at least one alcohol is provided.
BiomÉrieux


Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers


The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The Unversity Of Oxford


Method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation


The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the atm system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area..
Acubens


Method and measuring protein post-translational modification


The present invention includes a method for analyzing reactions. The method includes the steps of providing a solution of at least one acceptor chemical and at least one donor chemical.
Icagen, Inc.


Composition and methods for culturing cells


The present disclosure provides compositions for in vitro culture of cells. The present disclosure provides methods for in vitro culture of cells.
The Regents Of The University Of California




G Protein topics:
  • Antibodies
  • Nucleic Acid
  • G Proteins
  • Nucleic Acids
  • Amino Acid
  • Polypeptide
  • Protein A Affinity Chromatography
  • Chromatography
  • Chromatograph
  • Liver Metastasis
  • Membrane Protein
  • Colorectal Carcinoma
  • Rectal Carcinoma
  • Prophylactic
  • Glycoprotein


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7152

    4687

    1 - 1 - 103